What smart money is saying about Bio-Rad Laboratories, Inc.
3 funds in our archive have pitched Bio-Rad Laboratories, Inc., most recently AVI Global Trust in September 2026.
Bio-Rad Laboratories, Inc., established in 1952 and headquartered in Hercules, California, operates as a global provider of life science research and clinical diagnostic products. Its operations span across the United States, Canada, Europe, Asia, and Latin America. The company is organized into two primary divisions: Life Science and Clinical Diagnostics. The Life Science division is responsible for developing, manufacturing, and commercializing a diverse array of reagents, equipment, and laboratory instruments. These products are crucial for various research methodologies, biopharmaceutical manufacturing processes, and food quality testing. This segment focuses on specialized areas within the life sciences, including proteomics, genomics, biopharmaceutical production, cellular biology, and food safety. Its clientele encompasses academic institutions (such as universities and medical schools), industrial research organizations, government agencies, pharmaceutical companies, biotechnology firms, food producers, and food testing laboratories. In contrast, the Clinical Diagnostics division designs, produces, sells, and supports a comprehensive suite of test systems, informatics solutions, diagnostic kits, and specialized quality control products for clinical laboratories. This segment provides reagents, instruments, and software specifically tailored for particular niches within the in vitro diagnostics market. Its customer base includes reference laboratories, hospital laboratories, state newborn screening facilities, physicians' office laboratories, and transfusion laboratories. Beyond these core segments, Bio-Rad also offers systems and products designed to separate complex chemical and biological materials, as well as to identify, analyze, and purify their individual components. The company distributes its extensive product portfolio through a combination of its direct sales force and a network of third-party distributors, agents, brokers, and resellers.
Get an email when a fund buys, sells or pitches it
Fund signal · last 12 months
8 lettersFunds are split between buying and selling
Moves described in fund letters in our archive. A sentence published word for word by several funds of one house in the same quarter counts once.
Position history
Between Q3 2025 and Q3 2026, 8 fund letters reported a position in Bio-Rad Laboratories, Inc., with 3 buys (opened or added) and 3 sells (trimmed or exited).
| Quarter | Letters | Bought | Sold | Theses |
|---|---|---|---|---|
| Q3 2026 | 4 | 2 | 0 | 1 |
| Q2 2026 | 3 | 0 | 3 | 0 |
| Q1 2026 | 1 | 1 | 0 | 1 |
| Q3 2025 | 0 | 0 | 0 | 1 |
Bought and Sold count moves: the same sentence published by several funds of one house in a quarter counts once.
Fund activity · 8 positions · 8 moves
- New positionAVI Global TrustSeptember 2026
“Earlier in 2026 we established a position in Bio-Rad Labs (“Bio- Rad”).”
Bio-Rad Laboratories, Inc. - New positionAVI Global Special SituationsSeptember 2026
“Bio-Rad Labs: Earlier in 2026 we established a position in Bio-Rad Labs (“Bio- Rad”).”
Bio-Rad Laboratories, Inc. - New positionAVI Global Special SituationsAugust 2026
“Elsewhere in recent months we have established new positions in Mitsui O.S.K Lines (“MOL”) – the Japanese shipping company and Bio-Rad Labs, the US life sciences tools & diagnostics business that owns a listed stake in Sartorius AG.”
Bio-Rad Laboratories, Inc. - New positionAVI Global TrustAugust 2026
“AVI Global Trust’s (AGT) NAV increased by +4.0% in August. Samsung C&T was the top contributor (+81bps) as strong share price performance (+14%) was boosted by an appreciation of the Won against Sterling (+4.3%) Other strong contributors included Mitsui O.S.K Lines (+60bps), News Corp (+53bps) and Rohm (+40bps). In terms of detractors the most notable one was Jardine Matheson (-64bps). The shares have now de-rated substantially from a mid-20s discount earlier in the year to 41% currently. We have been adding to the position and believe one seller in particular has been weighing on the price. Mitsubishi Logistics (- 38bps) and Symphony International (-24bps) were the other detractors. As noted in previous newsletters the current environment is throwing up a lot of ideas in a variety of different markets. In Korea we have been adding to new and existing names such that at the time of writing we now have 15 Korean holdings; and we are increasingly enamoured about the opportunities for bottom-up engagement-focused investors in the mid-and-lower market cap part of the Korean market. Elsewhere in recent months we have established new positions in Mitsui O.S.K Lines (“MOL”) – the Japanese shipping company and Bio-Rad Labs, the US life sciences tools & diagnostics business”
Bio-Rad Laboratories, Inc. - June 2026
“In Health Care, we rebalanced within the sector, exiting Bio- Rad Laboratories and adding to medical device companies, which we believe offer greater upside, supported by product innovation and demographic-driven demand. Defensive sectors such as Consumer Staples and Utilities did not participate in the market rally. This created selective opportunities to increase quality defensive exposure, including a new position in Coca-Cola. We believe these additions enhance the portfolio’s ability to be resilient should markets experience a pullback. Across the portfolio, we continue to maintain our highest convictions in undervalued quality companies with the financial strength to withstand economic headwinds and positioned to benefit from long-term thematic tailwinds. Outlook Cautiously optimistic for quality value stocks to outperform We believe our balanced portfolio positioning, coupled with our holdings’ strong earnings growth potential and reasonable valuations, positions us well in the current market environment. That potential is supported by exposure to a range of secular tailwinds across sectors, giving the portfolio diversified paths to strong returns. Value stocks delivered compelling double-digit performance in the second quarter, supporting strong year- to-date returns. These results were supported by resilience in the wider economy, de-escalation in the Middle East, stable consumer spending and a continued broadening among AI investment beneficiaries. We remain cautiously optimistic for the rest of the year, supported by prospects for lower energy prices driving lower inflation, potential for accommodative fiscal policy in an election year and continued investment in AI infrastructure. Despite our optimism, we remain vigilant about a broad range of risks. Our quality orientation and a focus on embedding a margin of safety—both in stock selection as well as in portfolio construction—are essential to delivering attractive risk-adjusted returns. Additionally, our disciplined approach to rotating capital into holdings with better risk/reward profiles is integral to preserving capital during periods of elevated market uncertainty. As portfolio managers, we believe our deep experience in value investing underpins our ability to navigate these uncertain markets. We remain macro-aware, but our bottom- up investment process remains anchored in the fundamental analysis of company- and industry-specific dynamics. We believe fundamental factors often far outweigh short-term macro issues when one invests with a long-term time horizon. The efficacy of our time-tested approach is reflected in the strategy’s returns since inception, through various economic cycles. Parnassus Value Equity Fund | Investment Commentary - 2Q 2026 Quarterly Portfolio Activity Activity Security Name Ticker Sector Rationale Bought Coca-Cola Co. KO Consumer Staples Coca-Cola benefits from strong global brands, global distribution scale and durable pricing power supported by disciplined revenue growth management and strong fundamentals through market cycles. With majority volumes generated outside the U.S., the company is well positioned to capture long-term growth in emerging markets. Additionally, continued momentum in higher- growth beverage categories, including the Fairlife protein shake brand, supports a durable earnings growth outlook at a valuation we view as reasonable for the quality and resilience of the business. Sold Bio-Rad Laboratories Inc. BIO Health Care We exited Bio-Rad Laboratories as the risk/reward profile became less attractive at current valuation.”
Bio-Rad Laboratories, Inc. - June 2026
“In Health Care, we rebalanced within the sector, exiting Bio- Rad Laboratories and adding to Abbott Laboratories, a medical device leader that we believe offers greater upside, supported by product innovation and demographic-driven demand.”
Bio-Rad Laboratories, Inc. - ExitedLongleaf Partners FundJune 2026
“Portfolio Activity During the quarter, we purchased one new position in the portfolio. The new position is a healthcare company we know well and have made money owning previously. We look forward to discussing our case in more detail later. We exited our position in Bio- Rad after another disappointing operational quarter led us to conclude that our money would be better invested in the new holding.”
Bio-Rad Laboratories, Inc. - AddedAriel Focused ValueMarch 2026
“Additionally, we repurchased Bio-Rad Laboratories Inc. (BIO), a global leader in laboratory equipment and biological testing.”
Bio-Rad Laboratories, Inc.
Fund coverage · 3 theses
- AVI Global TrustSeptember 2026
Bio-Rad Laboratories combines a discounted sum-of-the-parts, a valuable Sartorius stake, and catalysts from restructuring and activism.
Read the full thesis - Ariel Focused ValueMarch 2026
Bio-Rad Laboratories Inc. is a global life sciences tools leader with rising margins, high recurring revenue, and dominant market positions supporting long-term growth.
Read the full thesis - Upslope CapitalSeptember 2025
Bio-Rad Laboratories is a leading global producer of clinical diagnostics and life sciences products, with a significant stake in Sartorius, suggesting an attractive valuation amidst recent market de-ratings.
Read the full thesis
Read every full thesis on Bio-Rad Laboratories, Inc.
Read all 3 theses in full, with each fund's reasoning, and get unlimited access to the archive.
View plans→